Nurix Therapeutics Inc. (NRIX)
Company Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders.
The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.
It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer.
The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018.
The company was incorporated in 2009 and is headquartered in San Francisco, California.

Country | United States |
IPO Date | Jul 24, 2020 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 286 |
CEO | Dr. Arthur T. Sands M.D., Ph.D. |
Advertisement
Contact Details
Address: 1700 Owens Street San Francisco, California United States | |
Website | https://www.nurixtx.com |
Stock Details
Ticker Symbol | NRIX |
Exchange | NASDAQ |
Fiscal Year | December - November |
Reporting Currency | USD |
CIK Code | 0001549595 |
CUSIP Number | 67080M103 |
ISIN Number | US67080M1036 |
Employer ID | 27-0838048 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Arthur T. Sands M.D., Ph.D. | Chief Executive Officer, President & Director |
Dr. Christine Ring J.D., Ph.D. | Chief Legal Officer, Secretary & Chief Compliance Officer |
Johannes Van Houte | Chief Financial Officer |
Christopher B. Phelps Ph.D. | Senior Vice President & Head of Early Drug Discovery |
Dr. Arthur Weiss M.D., Ph.D. | Founder & Member of Scientific Advisory Board |
Dr. Gwenn M. Hansen Ph.D. | Chief Scientific Officer |
Dr. Jason Kantor Ph.D. | Chief Business Officer |
Dr. John Kuriyan Ph.D. | Founder & Member of Scientific Advisory Board |
Dr. Pasit Phiasivongsa Ph.D. | Chief Technical Officer |
Rita Kwong | Senior Accounting Manager |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 23, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Apr 08, 2025 | 10-Q | Quarterly Report |
Apr 08, 2025 | 8-K | Current Report |
Mar 28, 2025 | DEFA14A | Filing |
Mar 28, 2025 | ARS | Filing |
Mar 28, 2025 | DEF 14A | Filing |
Mar 13, 2025 | 4 | Filing |
Mar 13, 2025 | 3 | Filing |
Mar 13, 2025 | 8-K | Current Report |
Mar 03, 2025 | 4 | Filing |